Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(06): 582-583DOI: 10.1055/s-0041-1740950 Report on International Publication Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease Aparna Sharma 1 Department of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India , Vibhor Sharma 2 Medical Oncology, Hematology and Bone Marrow Transplant, Paras Hospitals, Gurugram, Haryana, India › InstitutsangabenArtikel empfehlen Abstract Volltext Referenzen References 1 Zeiser R, Polverelli N, Ram R. et al; REACH3 Investigators. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 2021; 385 (03) 228-238 2 Jagasia M, Perales MA, Schroeder MA. et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood 2020; 135 (20) 1739-1749 3 Zeiser R, von Bubnoff N, Butler J. et al; REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 2020; 382 (19) 1800-1810 4 Wu H, Shi J, Luo Y. et al. Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation. JAMA Netw Open 2021; 4 (01) e2034750 5 Aslanis V, Umehara K, Huth F. et al. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. Cancer Chemother Pharmacol 2019; 84 (04) 749-757 6 Food and Drug Administration. Jakafi (ruxolitinib) tablets. Reference ID: 4191667. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202192s015lbl.pdf. Accessed December 8, 2021
